Overview

(IMPACT II) Molecular Profiling and Targeted Therapy in Treating Patients With Metastatic Cancer

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This randomized clinical trial studies how molecular profiling and targeted therapy work in treating patients with cancer that has spread to other places in the body compared to standard treatment. Information about genetic differences in a patient's tumor can be used to choose treatment that may target the tumor. It is not yet validated whether selecting treatment after studying the genetic changes that are associated with cancer in a patient's tumor is a better way to treat patients with metastatic cancer compared to therapy not based on studying the genetic changes that are associated with cancer.
Phase:
N/A
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Foundation Medicine
Tempus Labs